Alvotech ALVO

NAS: ALVO | ISIN: LU2458332611   15/12/2025
5,400 USD (-3,05%)
(-3,05%)   15/12/2025

16 december 2025 · Alvotech Launches $100 Million Senior Unsecured Convertible Bond Offering to Continue Strong Investment in R&D, Support Manufacturing, Global Product Launches and Enhance Liquidity Position, reaffirms 2025 outlook and provides 2026 guidance · Persbericht

11 december 2025 · Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman · Persbericht

3 december 2025 · Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman · Persbericht

24 november 2025 · Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area · Persbericht

20 november 2025 · Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab) · Persbericht

13 november 2025 · Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman · Persbericht

12 november 2025 · Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update · Persbericht

10 november 2025 · UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)          · Persbericht

6 november 2025 · Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA · Persbericht

4 november 2025 · Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update · Persbericht

2 november 2025 · Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05 · Persbericht

22 oktober 2025 · Alvotech Announces Changes in Global Business Development and Commercial Operations Team · Persbericht

6 oktober 2025 · European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency · Persbericht

22 september 2025 · European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva® · Persbericht

22 september 2025 · European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner · Persbericht

19 september 2025 · Alvotech Announces Marketing Approval in Japan of Three New Biosimilars · Persbericht

4 september 2025 · Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York · Persbericht

21 augustus 2025 · Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea® · Persbericht

20 augustus 2025 · Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia · Persbericht

13 augustus 2025 · Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update · Persbericht

Mijn selecties